EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

This was the stock's second consecutive day of losses.

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...